Reimbursement Rejection On Cost Grounds For “Highly Effective” Trodelvy In England
Country Out Of Sync With Other Project Orbis Markets On Gilead Product
In a draft decision NICE, the health technology appraisal body for England and Wales, has declined to recommend Gilead’s Trodelvy for triple negative breast cancer patients.
